|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
3751
|
CPFPX
|
3751.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference standard for [18F]CPFPX
8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine
|
|
|
|
|
|
|
|
|
Molar Mass: 322.38
|
|
|
C16H23FN4O2
|
|
|
[200557-18-2]
|
|
|
|
|
|
Colourless to off-white solid packaged in dark glass vials.
|
|
|
|
|
|
|
|
|
Purity: > 95 %
|
|
|
Certificates:
CoA; 1H and 19F NMR spectra
|
|
|
Chemical Name:
CA index name: 1H-Purine-2,6-dione, 8-cyclopentyl-3-(3-fluoropropyl)-3,9-dihydro-1-propyl-
|
|
|
Synonymes:
8-Cyclopentyl-3-(3-fluoro-propyl)-1-propyl-3,7-dihydro-purine-2,6-dione; 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine
|
|
|
Literature:
Holschbach M. H. et al. Synthesis and Evaluation of No-Carrier-Added 8-Cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX): A Potent and Selective A1-Adenosine Receptor Antagonist for in Vivo Imaging. J. Med. Chem. 2002, 45, 5150-5156.
|
|
|
Bauer A. et al. Evaluation of 18F-CPFPX, a Novel Adenosine A1 Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET. J. Nucl. Med. 2003, 44, 1682-1689.
|
|
|
Matusch A. et al. Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl. Med. Biol. 2006, 33, 891-898.
|
|
|
Elmenhorst D. et al. Caffeine Occupancy of Human Cerebral A1 Adenosine Receptors: In Vivo Quantification with 18F-CPFPX and PET. J. Nucl. Med. 2012, 53, 1723-1729.
|
|
|
|
|
|
date of product catalogue issue:
10 May 2017
|